PDF(Pubmed)
Abstract：
UNASSIGNED: Green tea intake has been reported to improve the clinical outcomes of patients with cardiovascular diseases or cancer. It may have a certain role in the development of venous thromboembolism (VTE) among cancer patients. The current study aimed to address this issue, which has been understudied.
UNASSIGNED: We carried out a retrospective study to explore the role of green tea intake in cancer patients. Patients with and without green tea intake were enrolled in a 1:1 ratio by using propensity scoring matching. The primary and secondary outcomes were VTE development and mortality 1 year after cancer diagnosis, respectively.
UNASSIGNED: The cancer patients with green tea intake (n = 425) had less VTE development (10 [2.4%] vs. 23 [5.4%], p = 0.021), VTE-related death (7 [1.6%] vs. 18 [4.2%], p = 0.026), and fatal pulmonary embolism (PE) (3 [0.7%] vs. 12 [2.8%], p = 0.019), compared with those without green tea intake (n = 425). No intake of green tea was correlated with an increase in VTE development (multivariate hazard ratio (HR) 1.758 [1.476-2.040], p < 0.001) and VTE-related mortality (HR 1.618 [1.242-1.994], p = 0.001), compared with green tea intake. Patients with green tea intake less than 525 mL per day had increased VTE development (area under the curve (AUC) 0.888 [0.829-0.947], p < 0.001; HR1.737 [1.286-2.188], p = 0.001) and VTE-related mortality (AUC 0.887 [0.819-0.954], p < 0.001; HR 1.561 [1.232-1.890], p = 0.016) than those with green tea intake more than 525 mL per day. Green tea intake caused a decrease in platelet (p < 0.001) instead of D-dimer (p = 0.297). The all-cause mortality rates were similar between green tea (39 [9.2%]) and non-green tea (48 [11.3%]) intake groups (p = 0.308), whereas the VTE-related mortality rate in the green tea intake group (7 [1.6%]) was lower than that of the non-green tea intake group (18 [4.2%]) (p = 0.026). The incidences of adverse events were similar between the green tea and non-green tea intake groups.
UNASSIGNED: In conclusion, the current study suggests that green tea intake reduces VTE development and VTE-related mortality in cancer patients, most likely through antiplatelet mechanisms. Drinking green tea provides the efficacy of thromboprophylaxis for cancer patients.
UNASSIGNED: We carried out a retrospective study to explore the role of green tea intake in cancer patients. Patients with and without green tea intake were enrolled in a 1:1 ratio by using propensity scoring matching. The primary and secondary outcomes were VTE development and mortality 1 year after cancer diagnosis, respectively.
UNASSIGNED: The cancer patients with green tea intake (n = 425) had less VTE development (10 [2.4%] vs. 23 [5.4%], p = 0.021), VTE-related death (7 [1.6%] vs. 18 [4.2%], p = 0.026), and fatal pulmonary embolism (PE) (3 [0.7%] vs. 12 [2.8%], p = 0.019), compared with those without green tea intake (n = 425). No intake of green tea was correlated with an increase in VTE development (multivariate hazard ratio (HR) 1.758 [1.476-2.040], p < 0.001) and VTE-related mortality (HR 1.618 [1.242-1.994], p = 0.001), compared with green tea intake. Patients with green tea intake less than 525 mL per day had increased VTE development (area under the curve (AUC) 0.888 [0.829-0.947], p < 0.001; HR1.737 [1.286-2.188], p = 0.001) and VTE-related mortality (AUC 0.887 [0.819-0.954], p < 0.001; HR 1.561 [1.232-1.890], p = 0.016) than those with green tea intake more than 525 mL per day. Green tea intake caused a decrease in platelet (p < 0.001) instead of D-dimer (p = 0.297). The all-cause mortality rates were similar between green tea (39 [9.2%]) and non-green tea (48 [11.3%]) intake groups (p = 0.308), whereas the VTE-related mortality rate in the green tea intake group (7 [1.6%]) was lower than that of the non-green tea intake group (18 [4.2%]) (p = 0.026). The incidences of adverse events were similar between the green tea and non-green tea intake groups.
UNASSIGNED: In conclusion, the current study suggests that green tea intake reduces VTE development and VTE-related mortality in cancer patients, most likely through antiplatelet mechanisms. Drinking green tea provides the efficacy of thromboprophylaxis for cancer patients.
摘要：
■据报道，绿茶可以改善心血管疾病或癌症患者的临床预后。它可能在癌症患者静脉血栓栓塞症（VTE）的发展中起一定作用。目前的研究旨在解决这个问题，这已经被充分研究了。
■我们进行了一项回顾性研究，以探讨绿茶摄入在癌症患者中的作用。通过使用倾向评分匹配，以1：1的比例招募有和没有绿茶摄入量的患者。主要和次要结果是癌症诊断后1年的VTE发展和死亡率。分别。
■摄入绿茶的癌症患者（n=425）的VTE发展较少（10[2.4％]与23[5.4%]，p=0.021),VTE相关死亡（7[1.6%]vs.18[4.2%]，p=0.026),和致命的肺栓塞（PE）（3[0.7%]vs.12[2.8%]，p=0.019),与不摄入绿茶的人相比（n=425）。不摄入绿茶与VTE发展增加相关(多变量风险比(HR)1.758[1.476-2.040]，p<0.001）和静脉血栓栓塞相关死亡率（HR1.618[1.242-1.994]，p=0.001),与绿茶相比。每天绿茶摄入量低于525毫升的患者VTE发展增加（曲线下面积（AUC）0.888[0.829-0.947]，p<0.001；HR1.737[1.286-2.188]，p=0.001）和VTE相关死亡率（AUC0.887[0.819-0.954]，p<0.001；HR1.561[1.232-1.890]，p=0.016）比每天绿茶摄入量超过525mL的人。绿茶摄入导致血小板减少(p<0.001)而不是D-二聚体(p=0.297)。绿茶（39[9.2%]）和非绿茶（48[11.3%]）组的全因死亡率相似（p=0.308），而绿茶摄入组的VTE相关死亡率(7[1.6%])低于非绿茶摄入组(18[4.2%])(p=0.026).绿茶和非绿茶摄入组的不良事件发生率相似。
■总而言之，目前的研究表明，摄入绿茶可以减少癌症患者的VTE发展和VTE相关死亡率，最有可能通过抗血小板机制。饮用绿茶为癌症患者提供了预防血栓的功效。
■我们进行了一项回顾性研究，以探讨绿茶摄入在癌症患者中的作用。通过使用倾向评分匹配，以1：1的比例招募有和没有绿茶摄入量的患者。主要和次要结果是癌症诊断后1年的VTE发展和死亡率。分别。
■摄入绿茶的癌症患者（n=425）的VTE发展较少（10[2.4％]与23[5.4%]，p=0.021),VTE相关死亡（7[1.6%]vs.18[4.2%]，p=0.026),和致命的肺栓塞（PE）（3[0.7%]vs.12[2.8%]，p=0.019),与不摄入绿茶的人相比（n=425）。不摄入绿茶与VTE发展增加相关(多变量风险比(HR)1.758[1.476-2.040]，p<0.001）和静脉血栓栓塞相关死亡率（HR1.618[1.242-1.994]，p=0.001),与绿茶相比。每天绿茶摄入量低于525毫升的患者VTE发展增加（曲线下面积（AUC）0.888[0.829-0.947]，p<0.001；HR1.737[1.286-2.188]，p=0.001）和VTE相关死亡率（AUC0.887[0.819-0.954]，p<0.001；HR1.561[1.232-1.890]，p=0.016）比每天绿茶摄入量超过525mL的人。绿茶摄入导致血小板减少(p<0.001)而不是D-二聚体(p=0.297)。绿茶（39[9.2%]）和非绿茶（48[11.3%]）组的全因死亡率相似（p=0.308），而绿茶摄入组的VTE相关死亡率(7[1.6%])低于非绿茶摄入组(18[4.2%])(p=0.026).绿茶和非绿茶摄入组的不良事件发生率相似。
■总而言之，目前的研究表明，摄入绿茶可以减少癌症患者的VTE发展和VTE相关死亡率，最有可能通过抗血小板机制。饮用绿茶为癌症患者提供了预防血栓的功效。
